Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL667557 | 0.97 | HSP90AA1 (0.35) | HSP90AA1PARP1P2RX7 | |
| Hydrochloric Acid SCHEMBL2392462 | 0.97 | HSP90AA1 (0.35) | HSP90AA1PARP1P2RX7 | |
| SCHEMBL19385802 | 0.90 | PARP1 (0.36) | HSP90AA1PARP1 | |
| SCHEMBL28475743 | 0.82 | OPRL1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL16113787 | 0.80 | OPRL1 (0.34) | — | |
| SCHEMBL15285749 | 0.77 | HDAC8 (0.32) | HSP90AA1HDAC8 | |
| SCHEMBL19385786 | 0.75 | MAOA (0.33) | HSP90AA1 | |
| Hydrochloric Acid SCHEMBL9899701 | 0.75 | HSP90AA1 (0.31) | HSP90AA1 | |
| Hydrochloric Acid SCHEMBL23610800 | 0.74 | — | — | |
| SCHEMBL19385796 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743422-B1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-13 | — | — | EP | claimed |
| EP-3798217-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-22 | — | — | EP | claimed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114599363-A | Combinations of CXCR7 antagonists with S1P1 receptor modulators | 爱杜西亚药品有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-05-24 | — | — | US | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| WO-2021084068-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-05-06 | — | — | WO | claimed |
| US-20210115033-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD. (CH) | 2021-04-22 | — | — | US | claimed |
| EP-3798217-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-03-31 | — | — | EP | claimed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | claimed |
| EP-3743422-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | Idorsia Pharmaceuticals Ltd (CH) | 2020-12-02 | — | — | EP | claimed |
| CN-111683945-A | Crystalline form of CXCR7 receptor antagonist (3S,4S) -1-cyclopropylmethyl-4- { [5- (2, 4-difluoro-phenyl) -isoxazole-3-carbonyl ] -amino } -piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl) -amide | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| CN-110563717-A | piperidine CXCR7receptor modulators | 爱杜西亚药品有限公司 | 2019-12-13 | — | — | CN | claimed |
| WO-2019145460-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-01 | — | — | WO | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | claimed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | claimed |
| EP-3743422-B1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-13 | — | — | EP | disclosed |
| EP-3743422-B1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-13 | — | — | EP | disclosed |
| EP-3743422-C0 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-13 | — | — | EP | disclosed |
| CN-111683945-B | Crystalline forms of CXCR7 receptor antagonists | 爱杜西亚药品有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-111683945-B | Crystalline forms of CXCR7 receptor antagonists | 爱杜西亚药品有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3798217-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-22 | — | — | EP | disclosed |
| EP-4051250-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | Idorsia Pharmaceuticals Ltd (CH) | 2022-09-07 | — | — | EP | disclosed |
| EP-4037670-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114599363-A | Combinations of CXCR7 antagonists with S1P1 receptor modulators | 爱杜西亚药品有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599363-A | Combinations of CXCR7 antagonists with S1P1 receptor modulators | 爱杜西亚药品有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-05-24 | — | — | US | disclosed |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-05-24 | — | — | US | disclosed |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-05-24 | — | — | US | disclosed |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20210355129-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2021084068-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084068-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-05-06 | — | — | WO | disclosed |
| US-20210115033-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD. (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20210115033-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD. (CH) | 2021-04-22 | — | — | US | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3798217-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| EP-3743422-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | Idorsia Pharmaceuticals Ltd (CH) | 2020-12-02 | — | — | EP | disclosed |
| EP-3743422-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | Idorsia Pharmaceuticals Ltd (CH) | 2020-12-02 | — | — | EP | disclosed |
| CN-111683945-A | Crystalline form of CXCR7 receptor antagonist (3S,4S) -1-cyclopropylmethyl-4- { [5- (2, 4-difluoro-phenyl) -isoxazole-3-carbonyl ] -amino } -piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl) -amide | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111683945-A | Crystalline form of CXCR7 receptor antagonist (3S,4S) -1-cyclopropylmethyl-4- { [5- (2, 4-difluoro-phenyl) -isoxazole-3-carbonyl ] -amino } -piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl) -amide | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111683945-A | Crystalline form of CXCR7 receptor antagonist (3S,4S) -1-cyclopropylmethyl-4- { [5- (2, 4-difluoro-phenyl) -isoxazole-3-carbonyl ] -amino } -piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl) -amide | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| CN-110563717-A | piperidine CXCR7receptor modulators | 爱杜西亚药品有限公司 | 2019-12-13 | — | — | CN | disclosed |
| WO-2019145460-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019145460-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-01 | — | — | WO | disclosed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | disclosed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-10150747-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-11 | — | — | US | disclosed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | disclosed |
| US-20180022723-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3262038-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2018-01-03 | — | — | EP | disclosed |
| EP-2812325-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2812325-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016137832-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-01 | — | — | WO | disclosed |
| US-9303020-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303020-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303020-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2331502-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2326633-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2812325-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2588464-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8722688-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8536338-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013119499-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013119499-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203775-A1 | Novel Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203775-A1 | Novel Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203775-A1 | Novel Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2588464-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | Bristol-Myers Squibb Company (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2545050-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8198449-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012003164-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-05 | — | — | WO | disclosed |
| US-8048887-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2331502-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2326633-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2010030592-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030538-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | HSP90AA1 543/4885PARP1 4642/4885P2RX7 1332/4885 |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-10150747-B2 | Compounds for the treatment of hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-20210115033-A1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | CXCR1, CXCR5, CXCR4 | HSP90AA1 1916/4885PARP1 3890/4885P2RX7 14/4885 |
| US-20130203775-A1 | Novel Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 370/4885PARP1 4335/4885P2RX7 3603/4885 |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 544/4885PARP1 4255/4885P2RX7 3621/4885 |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | HSP90AA1 1649/4885PARP1 2092/4885P2RX7 74/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 544/4885PARP1 4255/4885P2RX7 3621/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | HSP90AA1 1649/4885PARP1 2092/4885P2RX7 74/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | HSP90AA1 1626/4885PARP1 2285/4885P2RX7 101/4885 |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 544/4885PARP1 4255/4885P2RX7 3621/4885 |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 597/4885PARP1 3883/4885P2RX7 3428/4885 |
| US-20210355129-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, CDKN1A | HSP90AA1 2155/4885PARP1 2509/4885P2RX7 2021/4885 |
| US-20180022723-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | HSP90AA1 370/4885PARP1 4335/4885P2RX7 3603/4885 |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | CXCR1, CXCR5, CXCR4 | HSP90AA1 1900/4885PARP1 3900/4885P2RX7 13/4885 |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | HSP90AA1 2211/4885PARP1 4242/4885P2RX7 799/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | HSP90AA1 1626/4885PARP1 2285/4885P2RX7 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.